Open Beta
MetriLume

US marketsMIRM

SEC-sourced researchBeta

MIRM

Mirum Pharmaceuticals, Inc.

Company comparison ↗

Data passport

CIK
0001759425
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 6, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 186,374,000.0000 USD; December 2024: 336,888,000.0000 USD; December 2025: 521,312,000.0000 USD521.3M USD0 USD0December 2023December 2024December 2025
MIRM · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023186,374,000.0000Feb 25, 2026
December 2024336,888,000.0000Feb 25, 2026
December 2025521,312,000.0000Feb 25, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025521,312,000.0000-23,363,000.000055,827,000.0000842,813,000.0000528,123,000.0000Feb 25, 2026
December 2024336,888,000.0000-87,942,000.000010,325,000.0000670,754,000.0000445,114,000.0000Feb 25, 2026
December 2023186,374,000.0000-163,415,000.0000-70,944,000.0000——Feb 25, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$521.31MDecember 2025Feb 25, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$336.89MDecember 2024Feb 25, 202610-K
Net incomeNetIncomeLoss-$23.36MDecember 2025Feb 25, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$55.83MDecember 2025Feb 25, 202610-K
Total assetsAssets$842.81MDecember 2025Feb 25, 202610-K
Total liabilitiesLiabilities$528.12MDecember 2025Feb 25, 202610-K

New filings

Explore methodology ↗